Asia-based financial group launches $50M US biotech fund
Mirae Asset Capital Life Science has exited stealth mode with $50 million ready to go for certain U.S. biotechs.
Mirae Asset Capital Life Science has exited stealth mode with $50 million ready to go for certain U.S. biotechs.
CG Oncology is hoping to raise $209 million from its upcoming IPO, blazing a trail to the public markets that seems to be enticing more biotechs in the first month of the year.
Despite losing a couple of Big Pharma collaborators, Dewpoint Therapeutics is gearing up to finally take its lead biologic condensates into the clinic. But the biotech will need to clear out 18 unwanted roles and narrow its pipeline to make space for the right candidates.
Following a series of reports on the FDA’s alleged history of mishandling medical device recalls, which in turn sparked a request for a government probe of the regulator, the U.S. Government Accountability Office has agreed to take on the job.
BridgeBio Pharma is building a war chest for its showdown with Pfizer. Facing a deep-pocketed rival, the biotech has struck a set of financing deals worth up to $1.25 billion to support an anticipated launch and a schedule of phase 3 readouts for other assets.
As green shoots slowly push from the scorched Earth biotech markets, ReCode Therapeutics CEO Shehnaaz Suliman, M.D., is watching closely, biding her time for a potential second half IPO.
Roche has bagged a phase 3 win in TIGIT. But the victory falls short of being a clear-cut endorsement of the mechanism, with the use of a comparator that is no longer the standard of care complicating efforts to tease out the impact of the investigational antibody.
Windtree Therapeutics is heading back to the licensing well, using a familiar bucket to reel in more biobucks.
Kyverna Therapeutics has become the latest example of a growing new year trend for biotech IPOs, with the company hoping that going public will help fund its two lead CD19 CAR-T therapies through the clinic.
Genevant Sciences could be in line for over $114 million as part of a deal to combine its lipid nanoparticle tech with Tome Biosciences’ programmable genomic integration (PGI) expertise to develop an in vivo gene editing treatment for a rare liver disorder.